Vimarsana
Biggest News Aggregation in the World

Page 22 - Iagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iagnostics Today - Breaking & Trending Today

AI-assisted smartphone app performs well in skin cancer diagnosis - Vimarsana News

AI-assisted smartphone app performs well in skin cancer diagnosis

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which diagnosis and therapy of pigmented skin lesions benefit from it in a realistic clinical scenario.

Press release Biocartis Group NV: Four Abstracts Showing - Vimarsana News

Press release Biocartis Group NV: Four Abstracts Showing

PRESS RELEASE 20 October 2023, 07:00 CEST Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress...

Pioneering partnership supports early-stage innovation against antimicrobial resistance to save lives - Vimarsana News

Pioneering partnership supports early-stage innovation against antimicrobial resistance to save lives

Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced its first funding call with up to £10 million available to support innovators developing new antimicrobials.

One in five Norwegians suffering from inadequate tinnitus treatment - Vimarsana News

One in five Norwegians suffering from inadequate tinnitus treatment

Researchers have concluded that many people are suffering unnecessarily and that treatment provision offered to patients is failing at many levels.

Dr Lal PathLabs sheds 3% after Goldman Sachs downgrades stock to 'sell' - Vimarsana News

Dr Lal PathLabs sheds 3% after Goldman Sachs downgrades stock to 'sell'

Goldman forecasts a structural decline in volumes to high single digits from the previous estimate of double-digit volume growth. The firm has also said that the valuations of the B2C incumbent are stretched.